- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06085222
Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users (DISC)
September 16, 2025 updated by: Rick James Macatee, Florida State University
Refinement and Testing of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users
The prevalence of daily cannabis use and Cannabis Use Disorder (CUD) has increased in the United States over the past two decades.
Brief, computerized harm reduction interventions that target specific high-risk CUD populations could be an efficient approach to reducing CUD.
Distress intolerance , which refers to the tendency to negatively appraise and escape aversive emotional states, is a risk factor associated with stress-related cannabis use motivation and CUD severity/chronicity.
Thus, a brief, accessible, low-cost intervention that reduces distress intolerance in those with CUD and elevated distress intolerance could have a significant public health impact.
This proposed project aims to optimize an existing two-session computerized distress tolerance intervention and test its impact on distress intolerance and cannabis use outcomes in a randomized controlled trial.
Specifically, the intervention will be condensed to one-session, its active ingredient bolstered, and augmented with smart phone-delivered therapy reminders.
After obtaining feedback on the modified Emotional Engagement Distress Tolerance Intervention in a small sample, the intervention's efficacy compared to a stringent, credible, time-matched health education control intervention will be tested in a randomized controlled trial in 80 cannabis users with CUD and high distress intolerance.
Distress intolerance, cannabis use, and psychosocial functioning outcomes will be evaluated.
As an exploratory aim, a wristworn device will be used to measure objective stress responding in the real-world during the intervention period.
Our central hypothesis is that, compared to a control intervention, the Emotional Engagement Distress Tolerance Intervention will produce superior reductions distress intolerance, stress-related cannabis use motivation, disordered cannabis use, and psychosocial functioning.
Study Overview
Status
Recruiting
Conditions
Detailed Description
The prevalence of daily cannabis use and Cannabis Use Disorder (CUD) has increased in the United States over the past two decades.
Brief, computerized harm reduction interventions that target specific high-risk CUD populations could be an efficient approach to reducing CUD.
Distress intolerance, which refers to the tendency to negatively appraise and escape aversive emotional states, is a risk factor associated with stress-related cannabis use motivation and CUD severity/chronicity.
Thus, a brief, accessible, low-cost intervention that reduces distress intolerance in those with CUD and elevated distress intolerance could have a significant public health impact.
This proposed Stage I project aims to modify an existing two-session computerized distress tolerance intervention to optimize emotion regulation learning/generalization and test its impact on distress intolerance and cannabis use outcomes in a randomized controlled trial.
Specifically, the intervention will be condensed to one-session and its imaginal exposure module will be modified to shape emotional engagement with the aim of maximizing within-session habituation, which will be signaled with a novel audio/visual cue (habituation cue).
Habituation cues will then be delivered in just-in-time text message reminders triggered by naturalistic distress reported via ecological momentary assessment.
After obtaining feedback on the modified Emotional Engagement Distress Tolerance Intervention in a small sample, the intervention's efficacy compared to a stringent, credible, time-matched health education control intervention will be tested in a randomized controlled trial in 80 cannabis users with CUD and high distress intolerance.
To measure the intervention's mechanistic target engagement, multi-method distress intolerance assessments will be administered through four-month follow-up.
To measure the intervention's impact on cannabis use, stress-related cannabis use motivation (lab stress- elicited craving and neurophysiological drug cue reactivity, ecological momentary assessment of stress-elicited cannabis use) will be assessed through the intervention period.
Interviewer-assessed cannabis use frequency, CUD severity, and urinary THC metabolite concentration will be measured through 4-month follow-up.
Quality of life and anxiety/depression symptoms will also be measured as secondary outcomes through 4-month follow-up.
As an exploratory aim, a wristworn device will be used to measure ambulatory physiology during a portion of the intervention period to evaluate the feasibility of detecting heightened real- world distress based on objective indicators.
Our central hypothesis is that, compared to a control intervention, the Emotional Engagement Distress Tolerance Intervention will produce superior reductions in multi-method assessments of distress intolerance, stress-related cannabis use motivation, disordered cannabis use, and psychosocial functioning.
Successful completion of the proposed aims will (1) justify a subsequent Stage II trial, and (2) inform efforts to integrate the just-in-time habituation reminders with wearable technology in order to increase emotion regulation generalization opportunities and decrease participant report burden.
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zoe Howell Project Coordinator, BS
- Phone Number: 850-644-2445
- Email: brains@psy.fsu.edu
Study Locations
-
-
Florida
-
Tallahassee, Florida, United States, 32306-4301
- Recruiting
- The BRAINS Lab at Florida State University
-
Contact:
- Zoe Howell Study Coordinator, BS
- Phone Number: 850-644-2445
- Email: brains@psy.fsu.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Cannabis is the primary substance of abuse.
- Clinical-level Distress intolerance Index score.
- Current Cannabis Use Disorder diagnosis.
- Near-daily to daily cannabis use in past-month and past 3 months.
- Positive urine screen for THC
- Detectable skin conductance level
- Owns a smart phone
- Primary smoked/vaporized delta-9 or delta-8 THC user
Exclusion Criteria:
- Presence of acute/major psychiatric disturbance
- Current pregnancy
- Change in psychotropic medication within the past month
- Concurrently receiving treatment for cannabis use
- Concurrently receiving dialectical behavior therapy or exposure-based therapy for emotional disorders
- Planning to immediately quit using cannabis
- EEG contraindications
- Kidney disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Emotional Engagement Distress Tolerance Intervention
The experimental intervention (single 2.5 hour session) is comprised of video-delivered psychoeducation, adaptive skill practice, and emotional exposure.
During exposure, a sequence of percussive sounds accompanied by a visual depiction of the participant's skin conductance level during exposure will be presented at the moment the participant's skin conductance returns to the relaxation baseline value.
These images/sound will be intermittently sent to the participant's smart phone during the smart phone portion of the intervention.
|
2.5 hour computerized intervention with smart phone support focused on building tolerance of emotional distress
|
|
Placebo Comparator: Health Education Intervention
The health education control intervention is a single 2.5 hour computerized session.
It is comprised of audio-narrated videos on healthy habits and self-care in the domains of sleep, nutrition, hygiene, and physical exercise.
The same sequence of percussive sounds used in the Emotional Engagement Distress Tolerance Intervention is presented alongside summary slides presenting key points on healthy habits and self-care.
These images/sound will be intermittently sent to the participant's smart phone during the smart phone portion of the intervention.
|
2.5 hour computerized intervention with smart phone support focused on building healthy habits that support stress management
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Therapy Evaluation Questionnaire
Time Frame: Immediately after intervention session
|
acceptability/feasibility (credibility subscale range 3-27; expectancy item range 0%-100%; higher scores indicate better outcome)
|
Immediately after intervention session
|
|
Treatment Satisfaction Questionnaire
Time Frame: Post-Intervention (20 days after intervention session)
|
acceptability/feasibility (range 0-84; higher scores indicate better outcome)
|
Post-Intervention (20 days after intervention session)
|
|
Change in perceived distress intolerance from baseline through follow-up
Time Frame: Baseline, Mid-Intervention (10 days after intervention session), Post-Intervention (20 days after intervention session), One-Month Follow-up, Four-Month Follow-up
|
Distress Intolerance Index (range 0-40; higher scores indicate worse outcome) to assess perceived distress intolerance via self-report
|
Baseline, Mid-Intervention (10 days after intervention session), Post-Intervention (20 days after intervention session), One-Month Follow-up, Four-Month Follow-up
|
|
Change in behavioral distress intolerance from baseline through follow-up
Time Frame: Baseline, Mid-Intervention (10 days after intervention session), Post-Intervention (20 days after intervention session), One-Month Follow-up, Four-Month Follow-up
|
Mirror-Tracing Persistence Task to assess behavioral distress intolerance via computerized task
|
Baseline, Mid-Intervention (10 days after intervention session), Post-Intervention (20 days after intervention session), One-Month Follow-up, Four-Month Follow-up
|
|
Change in laboratory stress-induced cannabis craving from baseline through post-intervention
Time Frame: Baseline, Post-Intervention (20 days after intervention session)
|
Change in Marijuana Craving Questionnaire (range 11-77; higher scores indicate worse outcome) after Mannheim Multicomponent Stress Test at post-intervention compared to baseline
|
Baseline, Post-Intervention (20 days after intervention session)
|
|
Change in real-world stress-elicited cannabis use from baseline to post-intervention
Time Frame: Baseline, Mid-Intervention (10 days after intervention session), Post-Intervention (20 days after intervention session)
|
Change in stress->cannabis use slopes derived from ecological momentary assessment from baseline through post-intervention
|
Baseline, Mid-Intervention (10 days after intervention session), Post-Intervention (20 days after intervention session)
|
|
Change in cannabis use frequency from baseline through follow-up
Time Frame: Baseline, Post-Intervention (20 days after intervention session), One-Month Follow-up, Four-Month Follow-up
|
Change in cannabis use frequency (measured via timeline follow-back) from baseline through four-month follow-up
|
Baseline, Post-Intervention (20 days after intervention session), One-Month Follow-up, Four-Month Follow-up
|
|
Change in self-reported cannabis use problems from baseline through follow-up
Time Frame: Baseline, Post-Intervention (20 days after intervention session), One-Month Follow-up, Four-Month Follow-up
|
Change in Marijuana Problems Scale (range 0-38; higher scores indicate worse outcome) from baseline through follow-up
|
Baseline, Post-Intervention (20 days after intervention session), One-Month Follow-up, Four-Month Follow-up
|
|
Change in Cannabis Use Disorder symptoms from baseline through follow-up
Time Frame: Baseline, Four-Month Follow-up
|
Change in interviewer-assessed Cannabis Use Disorder criteria (range 0-11; higher scores indicate worse outcome) from baseline to four-month follow-up
|
Baseline, Four-Month Follow-up
|
|
Change in laboratory stress-induced neural reactivity to cannabis cues (assessed via the electroencephalography [EEG]-recorded late positive potential) from baseline through post-intervention
Time Frame: Baseline, Post-Intervention (20 days after intervention session)
|
Change in Late Positive Potential to Cannabis Cues after Mannheim Multicomponent Stress Test at post-intervention compared to baseline
|
Baseline, Post-Intervention (20 days after intervention session)
|
|
Change in urine tetrahydrocannabinol [THC] metabolite concentration from baseline through follow-up
Time Frame: Baseline, Mid-Intervention (10 days after intervention session), Post-Intervention (20 days after intervention session), One-Month Follow-up, Four-Month Follow-up
|
Change in urinary THC metabolite concentration (measured via ultra high performance liquid chromatography [UHPLC]) from baseline through four-month follow-up
|
Baseline, Mid-Intervention (10 days after intervention session), Post-Intervention (20 days after intervention session), One-Month Follow-up, Four-Month Follow-up
|
|
Change in Cannabis Demand from baseline to post-intervention
Time Frame: Baseline, Post-Intervention (20 days after intervention session)
|
Change in Omax, Breakpoint, and Elasticity derived from Marijuana Purchase Task (higher OMax/Breakpoint and lower Elasticity indicate worse outcome) at post-intervention compared to baseline
|
Baseline, Post-Intervention (20 days after intervention session)
|
|
Change in cannabis use quantity from baseline to post-intervention
Time Frame: Baseline, Post-Intervention (20 days after intervention session), One-Month Follow-up, Four-Month Follow-up
|
Change in cannabis use quantity (measured via timeline follow-back) from baseline through four-month follow-up
|
Baseline, Post-Intervention (20 days after intervention session), One-Month Follow-up, Four-Month Follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in quality of life from baseline through follow-up
Time Frame: Baseline, Post-Intervention (20 days after intervention session), One-Month Follow-up, Four-Month Follow-up
|
Change in self-reported quality of life (measured via Quality of Life Enjoyment and Satisfaction Questionnaire Short-Form; range 16-80; lower scores indicate worse outcome) from baseline through follow-up
|
Baseline, Post-Intervention (20 days after intervention session), One-Month Follow-up, Four-Month Follow-up
|
|
Change in depression and anxiety from baseline through follow-up
Time Frame: Baseline, Post-Intervention (20 days after intervention session), One-Month Follow-up, Four-Month Follow-up
|
Change in self-reported depression and anxiety (measured via Hospital Anxiety and Depression Scale [range 0-21 for each subscale; higher scores indicate worse outcomes) from baseline through follow-up
|
Baseline, Post-Intervention (20 days after intervention session), One-Month Follow-up, Four-Month Follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Richard J Macatee, PhD, Florida State University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 4, 2024
Primary Completion (Estimated)
October 30, 2027
Study Completion (Estimated)
October 30, 2027
Study Registration Dates
First Submitted
October 9, 2023
First Submitted That Met QC Criteria
October 13, 2023
First Posted (Actual)
October 16, 2023
Study Record Updates
Last Update Posted (Actual)
September 22, 2025
Last Update Submitted That Met QC Criteria
September 16, 2025
Last Verified
September 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00006346
- 1R34DA057733-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cannabis Use Disorder
-
University of MinnesotaNot yet recruitingCannabis Use | Cannabis Use DisorderUnited States
-
Indiana UniversityNational Institute on Drug Abuse (NIDA)RecruitingMarijuana Abuse | Marijuana Use | Addiction | Substance Use | Cannabis Dependence | Substance Use Disorders | Cannabis Use | Substance Abuse | Addiction, Substance | Marijuana Dependence | Substance Dependence | Marijuana Smoking | Cannabis Abuse | Cannabis Use Disorder | Marijuana | Cannabis Intoxication | Substance Related... and other conditionsUnited States
-
Brigham and Women's HospitalNot yet recruitingCannabis Use Disorder
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)Recruiting
-
Anders Fink-Jensen, MD, DMSciNeurobiology Research Unit, RigshospitaletRecruitingCannabis Dependence | Cannabis Abuse | Cannabis Use Disorder | Cannabis Use Disorders | Cannabis AddictionDenmark
-
Medical University of South CarolinaNational Cancer Institute (NCI)RecruitingTobacco Use Disorder | Marijuana Use | Tobacco Use Cessation | Cannabis Use | Cannabis Use DisorderUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingBipolar Disorder | Cannabis Use | Bipolar I Disorder | Cannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, Severe | Bipolar II Disorder | Schizoaffective Disorder, Bipolar TypeUnited States
-
Monash UniversityTurning PointCompletedCannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereAustralia
-
Oregon Research InstituteCompletedCannabis Use Disorder, Mild | Cannabis Use Disorder, ModerateUnited States
-
McMaster UniversityCenter for Medicinal Cannabis Research; Peter Boris Centre for Addictions Research...RecruitingCannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereCanada
Clinical Trials on Emotional Engagement Distress Tolerance Intervention
-
Peking UniversityNot yet recruitingEmotional Disorder | Emotional DistressChina
-
Peking UniversityCompleted
-
Peking UniversityNot yet recruiting
-
Peking UniversityNot yet recruitingEmotional DistressChina
-
Peking UniversityNot yet recruiting
-
Peking UniversityNot yet recruitingEmotional DistressChina
-
Peking UniversityThe Second Hospital of Anhui Medical University; The Affiliated Brain Hospital... and other collaboratorsRecruitingDepressive Disorder | Obsessive-Compulsive Disorder | Anxiety Disorders | Eating Disorders | Emotional Disorders | Post-Traumatic Stress Disorder, PTSDChina
-
Xinghua LiuNot yet recruiting
-
Peking UniversityNot yet recruitingEmotional DistressChina
-
Peking UniversityNot yet recruitingDepression, Anxiety | Emotional Distress